GENELUX CORPORATION APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
GENELUX CORPORATION (GNLX) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $429.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2023-08-14
- GENELUX CORPORATION apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2023-06-30 was $429.00K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month |
|---|---|---|
| 2023-06-30 | $429.00K 10-Q · filed 2023-08-14 | $627.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |